Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Alzheimer's Disease
Interventions: MK-1942, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more

Conditions: Alcohol Use Disorder
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years to 40 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: fingolimod, glatiramer acetate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 101
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: JNJ-64264681; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertriglyceridemia, Type 2 Diabetes
Interventions: DS102, Placebo; Drug
Lead sponsor: Afimmune; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 32
States / cities: Little Rock, Arkansas • Cerritos, California • Huntington Park, California + 24 more

Conditions: Neuroblastoma
Interventions: DFMO, Celecoxib, Cyclophosphamide, Topotecan; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 2 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Smallpox
Interventions: TPOXX, TPOXX Placebo; Drug · Other
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Miami, Florida • Orlando, Florida • Omaha, Nebraska + 5 more

Conditions: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts

Conditions: Hepatitis C
Interventions: ABT-072, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Clostridioides Difficile Infection
Interventions: CRS3123, Active Comparator; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Lancaster, California • Mission Hills, California + 14 more

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Larotrectinib (Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 21 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Fatigue
Interventions: Veillonella atypica FB0054, Placebo; Dietary Supplement · Other
Lead sponsor: FitBiomics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Carcinoma, Hepatocellular
Interventions: Refametinib (BAY86-9766); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 2 more

Conditions: Healthy Volunteer
Interventions: Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: Minocycline 100mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chapell Hill, North Carolina

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Anemia
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more

Conditions: Aging
Interventions: Probiotic - Lactobacillus Rhamnosus GG, Placebo; Dietary Supplement · Other
Lead sponsor: Kent State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Healthy Volunteers, Overweight
Interventions: Sucralose, Placebo; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Traumatic Brain Injury, Critical Illness, Sleep
Interventions: melatonin, placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF)
Interventions: PRT12396; Drug
Lead sponsor: Prelude Therapeutics Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Denver, Colorado + 7 more

Conditions: Obsessive-compulsive Disorder
Interventions: Cognitive-behavioral therapy, d-cycloserine, Pill placebo; Behavioral · Drug
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: St. Petersburg, Florida • Cambridge, Massachusetts

Search by objective public record fields.

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot)

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

A Study of the Next-generation Probiotic, Veillonella Atypica FB0054 vs Placebo

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions

Trial of Indomethacin in Chronic Pancreatitis

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Probiotic on Psychological and Cognitive Effects

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)